Vialwirebiotech, curated
November 21, 2026, 10:30 AM
September 24, 2026
- 10:57 AM · STAT News
- 9:57 AM · Pharmaceutical Technology9:57 AMEli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare — Pharmaceutical Technology
- 9:52 AM · STAT News9:52 AMSTAT+: Kyverna’s cell therapy shows lasting autoimmune benefit — STAT News
- 9:21 AM · STAT News9:21 AMSTAT+: The rise of the AI-native radiology practice — STAT News
- 6:30 AM · STAT News6:30 AMSTAT+: Why Gilead can’t stop talking about its ambitions in immunology — STAT News
- 6:22 AM · Pharmaceutical Technology6:22 AMPodcast: How Sandoz plans to harness its “golden decade” — Pharmaceutical Technology
- 5:46 AM · Drug Discovery World5:46 AMPhase III study supports lumateperone use in bipolar mania — Drug Discovery World
- 5:14 AM · Pharmaceutical Technology5:14 AMGenialis and Inventia to enhance pancreatic cancer treatment testing — Pharmaceutical Technology
- 4:29 AM · Pharmaceutical Technology4:29 AMBasecamp Research secures $140m for AI-driven therapies — Pharmaceutical Technology
- 4:00 AM · Drug Discovery World4:00 AMEC approves first triple-combination therapy for asthma maintenance — Drug Discovery World
- 2:29 AM · SCMP — Tech2:29 AMChinese drug Loberamisal extends stroke treatment window from 6 hours to 2 days — SCMP — Tech
September 23, 2026
- 10:00 PM · Science (News)10:00 PMNIH details $170 million biomedical research reproducibility effort — Science (News)
- 7:26 PM · STAT News7:26 PMWhite House plan to increase control of NIH grants appears ‘dead’ — STAT News
- 12:21 PM · BioPharma Dive12:21 PMRoche, Ionis RNA drug scores in kidney disease study — BioPharma Dive
- 12:19 PM · Bloomberg — Technology12:19 PMAnthropic Unveils Cheaper Claude Opus 5.5 Ahead of Expected IPO — Bloomberg — Technology
- 12:00 PM · BioWorld12:00 PMPalisade backs away but others not ‘scarred’ of FSCD — BioWorld
- 12:00 PM · BioWorld12:00 PMHHS pondering reclassification of islet cells for T1 diabetes — BioWorld
- 12:00 PM · BioWorld12:00 PMAnaconda snags $56M for work on tech platform for stroke — BioWorld
- 9:37 AM · STAT News9:37 AMSTAT+: Flagship gets a Pentagon contract — STAT News
- 9:00 AM · Drug Discovery World9:00 AMGrants support research into sleep mechanisms in Parkinson’s — Drug Discovery World
- 9:00 AM · BioWorld9:00 AMSamsung Life Public Welfare Foundation presents new HDAC6 inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMLexeo Therapeutics expands position in Friedreich’s ataxia — BioWorld
- 9:00 AM · BioWorld9:00 AMAnacalypsis Therapeutics raises pre-seed funding — BioWorld
- 9:00 AM · BioWorld9:00 AMNIH grant supports Alpharose’s rosiphersen for Bain syndrome — BioWorld
- 9:00 AM · BioWorld9:00 AMInnocare Pharma synthesizes new TYK2 JH2 domain inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMAxceso Biopharma presents new Bcr-Abl1-targeting PROTACs — BioWorld
- 9:00 AM · BioWorld9:00 AMEnvisagenics, Boehringer sign $1B deal for RNA splicing platform — BioWorld
- 9:00 AM · BioWorld9:00 AMViva-Thera nominates MPER-targeted HIV-1 candidate — BioWorld
- 9:00 AM · BioWorld9:00 AMNovartis locks in preclinical RLT under $900M Boomray deal — BioWorld
- 9:00 AM · BioWorld9:00 AMNew SOX18 inhibitors reported in Gertrude Biomedical patent — BioWorld
- 9:00 AM · BioWorld9:00 AMFDA clears IND for Systimmune’s bispecific antibody SI-B037 — BioWorld
- 9:00 AM · BioWorld9:00 AMAdagene’s ADG-138 cleared for clinic in China for solid tumors — BioWorld
- 7:02 AM · Drug Discovery World7:02 AMFunding boost transforms AI-enabled biological innovation — Drug Discovery World
- 5:00 AM · Drug Discovery World5:00 AMAriadne Bio spins out to target apathy in Parkinson’s disease — Drug Discovery World
- 12:00 AM · FT — Pharmaceuticals12:00 AMOzempic-maker Novo open to upgrading US listing — FT — Pharmaceuticals
September 22, 2026
- 11:56 PM · Bloomberg — Technology11:56 PMHeidi CEO on AI in Healthcare, $900M valuation — Bloomberg — Technology
- 8:45 PM · SCMP — Tech8:45 PMChina’s cancer breakthrough on CAR-T cell therapy shows progress — SCMP — Tech
- 4:30 PM · Nikkei Asia4:30 PMRoche-owned Chugai Pharma to ramp up in-house output with 50% capex boost — Nikkei Asia
- 2:31 PM · BioPharma Dive2:31 PMAmgen reports a Phase 3 win with Sjögren’s drug candidate — BioPharma Dive
- 12:31 PM · Pharmaceutical Executive12:31 PM<![CDATA[Nine European Drugmakers Warn the Continent Risks Losing the Pharma Investment Race: Report ]]> — Pharmaceutical Executive
- 12:10 PM · BioPharma Dive12:10 PMViking shares surge on updated obesity drug data — BioPharma Dive
- 12:00 PM · BioWorld12:00 PMUncertainty continues as Wuxi Apptec haunted by listing — BioWorld
- 12:00 PM · BioWorld12:00 PMSK Biopharm takes 1st Bio’s LRRK2/c-Abl inhibitor in $315M deal — BioWorld
- 12:00 PM · BioWorld12:00 PMDLL3 drug race expands beyond bispecific T-cell engagers — BioWorld
- 12:00 PM · BioWorld12:00 PMSecond Chimagen deal extends GSK's China innovation strategy — BioWorld
- 12:00 PM · BioWorld12:00 PMChina syndrome? Phase II wins for Cue in CSU, stock melts down — BioWorld
- 12:00 PM · BioWorld12:00 PMCompass drops on FDA feedback for tovecimig in biliary cancer — BioWorld
- 12:00 PM · BioWorld12:00 PMDialybrid raises €15M for Silkothane Arteriovenous Graft — BioWorld
- 12:00 PM · BioWorld12:00 PMSino Biopharm nears approvals with HER2 ADC, IL-4R antibody filings — BioWorld
- 12:00 PM · BioWorld12:00 PMHighlife secures $90M+ to advance its TMVR system — BioWorld
- 12:00 PM · BioWorld12:00 PMRegcell adds $66M to take Nobel-winning Tregs to clinic — BioWorld
- 11:42 AM · BioPharma Dive11:42 AMCelldex sinks as safety concerns cloud immune drug results — BioPharma Dive